The metallothionein (MT) expression is used as a prognastic factor for tumor progression and drug resistance in a variety of malihgnancies particularly breast, hepatic, prostatic, ovarial, head and neck, non - small cell lung carcinoma, and soft tissues sarcoma. The latest research outcomes indicate that MT levels in cancerous cells indicate the clinical stage of the disease or response to therapy. MT plays a key role in transport of essential heavy metals, detoxification of toxic metals and protection of cells against oxidation stress. Aim: The goal of this study was to see the MT isoforms (MT1A, MT1E, MT1F, MT1H, MT1X, MT2A) expression in MN1 (human breast cancer epithelial cell line containing wild type – p53) and MDD 2 (derived from MCF7 cell line, containing mutated p53) and HEPG 2 cell lines. Materials and Methods: After designing all the above set of primes and adjusting the gradient temperature for the Polymerase Chain Reaction (PCR). The RNA is extracted and made complementary DNA from it. Results: After several numbers of polymerase reactions and number of repetitions our data suggest that MT isoforms are not expressed in MN and MDD2 cell line, but they are expressed in HEPG 2 cell lines.

Keywords: Metallothionein Ioforms; p53.